Us Markets 2

Us Markets 2 News

SpaceX at $2.5 Trillion: Three Analyst Takes on Whether the Valuation Is Justified

Three analyst perspectives on SpaceX'\''s $2.5 trillion implied private market valuation offer divergent conclusions on whether Starlink and Starship fundamentals can support the figure.

Jun 20, 2026

Etf

Virtus InfraCap PFFA ETF Returns -3.39% in Q1 2026, Trailing Benchmark by 103 Basis Points

PFFA's Q1 2026 commentary shows a NAV return of -3.39%, underperforming its benchmark by 103 basis points as preferred stock market conditions remained challenging in the rate-sensitive segment.

Jun 20, 2026

Pharma

Teva's Austedo Franchise Drives 72% Year-Over-Year EPS Growth with Positive New Trial Data

Teva Pharmaceutical delivered strong Q1 2026 results driven by its Austedo/Austedo XR tardive dyskinesia franchise, with EPS up 72% year-over-year and positive new clinical study data.

Jun 20, 2026

US Markets

Enova International and Ligand Pharmaceuticals Both Clear Analyst Price Targets

Shares of consumer lender Enova International and pharma royalty company Ligand Pharmaceuticals surpassed consensus analyst price targets, signaling potential upside reassessment.

Jun 20, 2026